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Gene expression of vitamin D hydroxylase and megalin in the
remnant kidney of nephrectomized rats.
Background. Regulation of vitamin D hydroxylase genes in
the early stage of chronic renal failure is not fully understood.
Using nephrectomized rats, we examined changes in mRNA
levels of CYP27B1 (25-hydroxyvitamin D3-1-hydroxylase),
CYP24 (25-hydroxyvitamin D3-24-hydroxylase), and vitamin
D receptor in relation to megalin, recently found to participate
in renal vitamin D metabolism.
Methods. A rat model of moderate renal failure was induced
by 3/4 nephrectomy. Plasma parameters, including vitamin D
metabolite concentrations, were measured at weeks 2, 4 and
8, and poly(A) RNA extracted from the remnant kidneys was
subjected to Northern blot hybridization.
Results. Plasma creatinine concentration at week 2 was
0.40 0.02 mg/dL in the sham-operated and 0.93 0.15 mg/dL
in the nephrectomized rats, and both values remained constant
up to week 8. Plasma concentrations of 25(OH)D3, 1,25
(OH)2D3, and 24,25(OH)2D3 were unchanged between nephrec-
tomized and sham-operated rats at week 8. Intact parathyroid
hormone (PTH) increased at week 8 in nephrectomized rats.
CYP27B1 mRNA in nephrectomized rats did not vary at
week 2, but increased approximately two- and four-fold at
weeks 4 and 8, respectively, compared to the sham-operated
rats. CYP24 and megalin mRNAs, on the other hand, began
to decline as early as at week 2 in nephrectomized rats and
kept decreasing throughout the experiment. The expression of
vitamin D receptor was modestly but significantly decreased
only at week 8.
Conclusion. Coordinated and reciprocal alterations of the
increase in CYP27B1 mRNA and the decrease in CYP24
mRNA may play a pivotal role in maintaining the plasma level
of 1,25(OH)2D3 in the face of reduced nephron mass and/or
megalin expression.
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The most critical step in the regulation of vitamin D
metabolism is the renal conversion of 25-hydroxyvitamin
D3 [25(OH)D3] to 1,25-dihydroxyvitamin D3 [1,25(OH)2D3]
catalyzed by mitochondrial 25(OH)D3-1-hydroxylase
(CYP27B1). Another important enzyme in this process
is 1,25(OH)2D3-24-hydroxylase (CYP24), which breaks
down 1,25(OH)2D3 and uses the 25(OH)D3 as a substrate
to produce 24,25-dihydroxyvitamin D3 [24,25(OH)2D3].
Thus, a balance between CYP27B1 and CYP24 may be
one of the major determinants in maintaining the plasma
level of 1,25(OH)2D3. In addition, both enzymes are
regulated by several hormones and ions.
It is believed that a decrease in 1,25(OH)2D3 synthe-
sis plays a key role in generating secondary hyperpara-
thyroidism in the setting of chronic renal failure [1]. The
mechanism of the decrease in 1,25(OH)2D3 was thought
to be simply due to the diminished renal mass [2] and thus
to the reduced enzyme activity of CYP27B1 localized in
the proximal tubules. However, the plasma concentra-
tion of 1,25(OH)2D3 remains within normal range in
chronic renal failure with a glomerular filtration rate (GFR)
above 30 to 40 mL/min [3, 4]. Therefore, the mechanism
of the normal plasma concentration of 1,25(OH)2D3 in
this moderate renal failure is probably due to a decrease
in degradation of 1,25(OH)2D3 [5]. Nonetheless, it has
not been clearly shown whether the enzymatic activity
is reduced or the gene expression itself is reduced.
Recent evidence has suggested that megalin may be
a player involved in renal vitamin D metabolism because
megalin knockout mice were unable to retrieve 25(OH)D3
from the glomerular filtrate, resulting in vitamin D defi-
ciency [6]. Megalin, which has long been called gp330,
was originally ascribed as a causative antigen for inducing
experimental membranous nephropathy in rats [7, 8].
The protein exists at the intermicrovillar domains of the
apical membrane of the proximal tubules. Later, megalin
was found to be a multifunctional clearance receptor by
means of endocytosis of the many proteins that filter
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through the glomeruli [9], including vitamin D binding
protein [6].
Therefore, it may be possible that megalin plays some
role in vitamin D metabolism in chronic renal failure
and in secondary hyperparathyroidism as well. To ex-
plore the molecular events of vitamin D hydroxylase
gene expression occurring in the early stage of chronic
renal failure, the mRNA levels of CYP27B1 and CYP24
in the remaining kidney of nephrectomized rats were
measured as a function of time with particular reference
to megalin expression.
METHODS
Chemicals
All chemicals were of highly purified analytical grade.
[-32P] deoxycytidine triphosphate (dCTP) was purchased
from DuPont/New England Nuclear (Boston, MA, USA),
and the random primed DNA labeling kit was obtained
from TaKaRa Biomedicals (Shiga, Japan).
Animals
Adult male Sprague-Dawley rats (250 to 280 g) (Japan
Clea, Tokyo, Japan) were used. The animals were main-
tained with a standard commercial diet containing 1.09%
calcium and 0.93% phosphorus (Japan Clea) and housed
at an ambient temperature of 22C with an alternating
12-hour light and 12-hour dark cycle. After a 3-day adap-
tation period, the animals were randomly allotted to sham-
operation or 3/4 nephrectomy groups. Three-fourths ne-
phrectomy was done in one step by performing right
nephrectomy and a resection of both poles of the left
kidney yielding half the weight, as reported previously
[10]. One day before weeks 2, 4, and 8 following nephrec-
tomy and sham-operation, the rats were individually
housed in a metabolic cage and sacrificed the following
day. Blood samples were drawn by puncture of the ab-
dominal aorta and the remnant kidney was excised and
subjected to total RNA extraction.
The animal studies were performed in accordance with
the guidelines of the Toranomon Hospital Committee
on Animal Research.
Biochemical determination of blood and urine
Plasma urea nitrogen, creatinine, calcium, and phos-
phorus were measured by automated analysis (Model
AU-550; Olympus, Tokyo, Japan). Plasma intact para-
thyroid hormone (PTH) was measured using an intact
PTH enzyme-linked immunosorbent assay (ELISA) kit
(Immutopics, San Clemente, CA, USA). Plasma vitamin
D3 metabolites were measured by competitive protein
binding assay using a vitamin D–deficient serum.
Urinary protein concentration was measured by the
pyrogallol red method (Wako Pure Chemical Industries,
Ltd., Osaka, Japan). Urinary creatinine concentration
measured similarly to the plasma creatinine was used
for the calculation of creatinine clearance.
Northern blot analysis
Total RNA from the remnant kidney was prepared
by the acid guanidinium thiocyanate-phenol-chloroform
procedure using Trizol (Gibco BRL, Life Technologies,
Inc., Gaithersburg, MD, USA). Polyadenylated [poly
(A)]-enriched RNA was purified using Oligotex dT 30
(TaKaRa Biomedicals). Five micrograms of poly(A)
RNA was separated by electrophoresis in denaturing
agarose gels (2.2 mol/L formaldehyde and 1.5% agarose),
transferred to a nylon membrane by diffusion (Hybond
N; Amersham Pharmacia Biotech, Bucks, United King-
dom), and cross-linked by ultraviolet irradiation. Hy-
bridization was performed as described previously [11].
The following cDNA fragments were used as probes:
a 1.5 kb Eco RI-Bam HI fragment of rat cDNA encoding
CYP27B1 [11], a 1.8 kb Kpn I and Acc I fragment of rat
cDNA encoding CYP24 [12], a 0.4 kb Eco RI fragment of
rat cDNA encoding megalin [8], a 1.8 kb Eco RI frag-
ment of rat cDNA encoding vitamin D receptor (VDR)
[13] and a 0.4 kb Hinf I fragment of human cDNA encod-
ing -actin.
The membranes were analyzed by a PhosphorImager
(Bas 2000; Fuji Film, Tokyo, Japan) and then subjected
to autoradiography (X-Omat; Eastman Kodak, Roches-
ter, NY, USA). The same membrane was used for the
subsequent hybridizations with other probes after strip-
ping. The expression of -actin mRNA was used as an
internal reference standard according to a previous re-
port [14, 15]. -actin mRNA expression was observed
to be unaffected by nephrectomy when an equal amount
of poly(A) RNA from either the sham-operated or
nephrectomized rats was loaded in each lane during each
experiment.
Statistical analysis
All numerical data are expressed as mean  SD. Data
between two groups were analyzed by the unpaired t
test, and data among three groups were analyzed by
analysis of variance (ANOVA) followed by Bonferroni’s
post hoc test (significance was attained where P 
0.0167). A P value less than 0.05 was considered signifi-
cant unless otherwise stated.
RESULTS
Animal data
Body weights of the nephrectomized rats were always
lower than those of the sham-operated rats at the respec-
tive experimental date as shown in Table 1. Hematocrit
of the nephrectomized rats decreased with time com-
pared with that of the control rats, probably due to the
progression of renal anemia. The plasma concentrations
of urea nitrogen as well as creatinine were stable in
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Table 1. Body weight and biochemical parameters in sham-operated and nephrectomized rats at weeks 2, 4, and 8 after nephrectomy
Week 2 4 8
Body weight g
Sham-operated 36917 43413b 47617b,c
Nephrectomized 32412a 36232a 43625a,b,c
Hematocrit %
Sham-operated 391 402 453b,c
Nephrectomized 395 352a 373a
Plasma urea nitrogen mg/dL
Sham-operated 212 212 172
Nephrectomized 608a 617a 5410a
Plasma creatinine mg/dL
Sham-operated 0.400.02 0.430.03 0.400.01
Nephrectomized 0.930.15a 0.950.11a 1.100.30a
Creatinine clearance mL/min
Sham-operated 2.140.33 2.690.39 4.040.77b,c
Nephrectomized 0.890.18a 0.960.18a 1.190.25a,b
Urinary protein mg/day
Sham-operated 6.52.8 9.95.0 7.23.6
Nephrectomized 5.72.5 12.66.4 33.017.5a,b,c
Results are expressed as meanSD of five rats (sham-operated) and eight rats (nephrectomized).
aP  0.05 vs. sham-operated
bP  0.0167 vs. week 2
cP  0.0167 vs. week 4
Fig. 1. Time course of plasma concentrations of calcium (A ), phos-
phorus (B ), parathyroid hormone (PTH) (C ), and 1,25(OH)2D3 (D )
in the sham-operated () and nephrectomized rats (). Measure-
ment was performed at weeks 2, 4, and 8 after nephrectomy. Data are
mean  SD of five rats (sham-operated) and eight rats (nephreto-
mized). *P  0.05 vs. sham-operated rats; †P  0.0167 vs. week 2;
‡P  0.0167 vs. week 4.
the sham-operated control, whereas those values in the
nephrectomized rats doubled at week 2 and remained
constant thereafter. Creatinine clearance in the nephrec-
tomized rats ranged from 30% to 40% of that of the
control throughout the experiment. These renal function
data are consistent with the moderate degree of renal
failure reported by a previous observation [16]. Urinary
protein excretion only increased in the nephrectomized
rats at week 8.
Table 2. Plasma concentration of vitamin D metabolites at week 8
after nephrectomy
25(OH)D3 1,25(OH)2D3 24,25(OH)2D3
ng/mL pg/mL ng/mL
Sham-operated 24.84.5 70.76.8 8.00.6
Nephrectomized 39.315.0 76.910.5 8.63.1
Values are expressed as meanSD of five (sham-operated) and eight rats
(nephrectomized).
Blood chemistry
Timed changes in the plasma concentrations of cal-
cium, phosphorus, intact PTH, and 1,25(OH)2D3 are
shown in Figure 1. Plasma calcium transiently increased
at week 4 in the nephrectomized rats, but did not change
with time in the sham-operated animals. Plasma phos-
phorus increased at week 4 and decreased at week 8,
but no difference was obtained between the sham-oper-
ated and nephrectomized rats.
Intact PTH in the nephrectomized rats appeared to
increase with time but was not significant (P  0.108).
When compared to the sham-operated rats, intact PTH
at week 8 was significantly greater in the nephrectomized
rats (P  0.040) as shown in Figure 1C. Plasma 1,25
(OH)2D3 decreased at week 8 in both the sham-operated
and nephrectomized rats but no significant difference
was achieved between the two (Fig. 1D).
With respect to other vitamin D metabolites, the plasma
concentrations of 25(OH)D3 and 24,25(OH)2D3 were mea-
sured by competitive protein binding assay (CPBA) using
vitamin D–deficient serum (Table 2). In addition to there
being no changes in 1,25(OH)2D3 between the sham-
operated and nephrectomized rats, the other two metab-
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Fig. 2. Northern blot of CYP27B1, CYP24, megalin, and vitamin D
receptor (VDR) mRNAs at week 2 in the sham-operated and nephrec-
tomized rats. Messenger RNA expression of the target genes was
corrected for respective -actin mRNA by reprobing. Values are
mean  SD of 7 and 11 rats for sham-operated and 3/4 nephrectomy
(Nx), respectively. ***P  0.001.
olites did not vary either. No correlation was found be-
tween any two variables among the three metabolites in
the sham-operated group or nephrectomized group (data
not shown).
Northern blot analysis of CYP27B1, CYP24, megalin,
and VDR expression
Next, we performed Northern blot analysis to examine
the gene expression of CYP27B1, CYP24, megalin, and
VDR in the sham-operated (N 7) and nephrectomized
rats (N 11) at weeks 2, 4, and 8 following nephrectomy.
The expression of these genes was corrected for -actin
expression of the same blot filter by reprobing. While
CYP27B1 or VDR mRNA expression was unaltered,
the expression of CYP24 and megalin mRNAs were sig-
nificantly decreased at week 2, compared with those in
the sham-operated rats (Fig. 2). At week 4, CYP27B1
mRNA began increasing in the nephrectomized rats
while CYP24 and megalin mRNAs were decreased (Fig.
3). Finally, at week 8, an increase in CYP27B1 mRNA
was more evident in the nephrectomized rats and the
decreases in both CYP24 and megalin mRNA were still
observed (Fig. 4). In addition, VDR mRNA was de-
creased by half in the nephrectomized rats at week 8
(Fig. 4). A representative result obtained from the sham-
operated and nephrectomized rats at week 8 is shown
in Figure 5.
DISCUSSION
The 3/4 nephrectomy rat model used in the present
study exemplified a moderate degree of renal failure
ranging from 30% to 40% of residual renal function.
The degree of renal failure is thought to be less severe
than that of 5/6 nephrectomy at the same experimental
time after nephrectomy [10]. Our renal function data
Fig. 3. Northern blot of CYP27B1, CYP24, megalin, and vitamin D
receptor (VDR) mRNAs at week 4 in the sham-operated and nephrec-
tomized rats. Messenger RNA expression of the target genes was
corrected for respective -actin mRNA by reprobing. Values are
mean  SD of 7 and 11 rats for sham-operated and 3/4 nephrectomy
(Nx), respectively. *P  0.05; **P  0.01.
Fig. 4. Northern blot of CYP27B1, CYP24, megalin, and vitamin D
receptor (VDR) mRNAs at week 8 in the sham-operated and nephrec-
tomized rats. Messenger RNA expression of the target genes was
corrected for respective -actin mRNA by reprobing. Values are
mean  SD of 7 and 11 rats for sham-operated and 3/4 nephrectomy
(Nx), respectively. **P  0.01; ***P  0.001.
almost corroborated with the previously reported data
of moderate renal failure induced by 5/6 nephrectomy
for 2 weeks [16]. In fact, the 3/4 nephrectomy rats re-
vealed no significant change in the plasma levels of cal-
cium, phosphorus, or 1,25(OH)2D3 compared to the
sham-operated control rats over 8 weeks (the maximal
observation period of the present study). The findings
are quite similar to a moderate degree of renal failure
in which the serum concentration of 1,25(OH)2D3 is
kept constant as well as calcium and phosphorus [17, 18].
Thus, the 3/4 nephrectomy rat model turned out to be
suitable for the present study since we aimed at investi-
gating the timed changes in vitamin D hydroxylase gene
expression. Plasma intact PTH at week 8 was found to
increase in the nephrectomized rats when compared to
that of the sham-operated rats, suggesting that the very
early stage of secondary hyperparathyroidism might be-
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Fig. 5. Northern hybridization of CYP27B1, CYP24, megalin, and
vitamin D receptor (VDR) mRNAs from the sham-operated and ne-
phrectomized (Nx) at week 8. Sizes of the respective mRNA are shown
to the right.
gin in order to compensate for calcium and vitamin D
metabolism.
Using this 3/4 nephrectomy model, we demonstrated
that the expression of CYP27B1 mRNA was significantly
increased at week 8 in the remnant kidneys, compared
with that in the sham-operated rats. Since plasma PTH
concentration was elevated at week 8, the observed in-
crease in CYP27B1 mRNA level can be ascribed to PTH-
dependent mechanisms, as underscored by the currently
prevailing notion [1]. In keeping with this view, Mura-
yama et al [19] found that in a more advanced 5/6 ne-
phrectomy rats, CYP27B1 mRNA expression was poorly
responsive to PTH administration, leading to a decrease
in CYP27B1 mRNA in the face of a marked increase in
plasma PTH. In addition, their study revealed a slight,
yet, significant increase in the plasma phosphorus [19].
In this regard, hyperphosphatemia has been known to
decrease the enzymatic activity of CYP27B1 as well as
the concentration of plasma 1,25(OH)2D3 [17, 20, 21],
while reduction in the plasma phosphorus has been
shown to be a stimulator of the plasma 1,25(OH)2D3
[22, 23] . In fact, we showed previously that the expres-
sion of CYP27B1 gene is moderately stimulated in re-
sponse to a low phosphorus diet [11]. These observations
suggest that in the moderate stage of renal failure with
increased PTH and the normal level of plasma phospho-
rus, CYP27B1 gene is up-regulated via PTH-dependent
mechanisms, contributing to the maintenance of plasma
1,25(OH)2D3. As loss of functioning nephrons prog-
resses, the remnant kidney advances to a state where
PTH responsiveness of renal cells is diminished, allowing
a decrease in CYP27B1 mRNA.
In contrast, the expression of CYP24 gene decreased
as early as week 2, well before the elevation of PTH.
Several studies have suggested that the renal 24-hydrox-
ylation reaction of 25(OH)D3 is reduced in renal failure
[5, 16, 24–26]. In accordance with these findings, the
expression of renal CYP24 mRNA in the nephrecto-
mized rats was lower than that in the sham-operated rats
throughout the experiment, whereas the plasma level of
24,25(OH)2D3 did not differ in the present study. The
mechanism of reduced CYP24 mRNA may involve sev-
eral elements. First, PTH is known to inhibit CYP24 in
the kidney [27, 28]. Second, down-regulation of VDR
may be involved; VDR mRNA was indeed decreased at
week 8 as shown in the present study. Transcription of
the CYP24 gene is regulated by the cis-arrayed vitamin
D responsive element upon binding to a complex of
VDR, 1,25(OH)2D3, and retinoid X receptor [29]. How-
ever, the fact that both the increase in PTH and the
modest decline in VDR mRNA were found only at week
8 in the present study may not fully account for the
mechanism. Uremic toxins, for example, could be taken
into consideration. Indeed, Hsu, Patel, and Young [26]
reported that uremic plasma ultrafiltrate decreases 24-
hydroxylase activity, thereby reducing 1,25(OH)2D3
degradation.
Taken together, it is worth mentioning about the bal-
ance between two hydroxylase genes, CYP27B1 and
CYP24, in reduced nephron mass. Despite having one-
fourth the nephron mass the plasma concentration of
1,25(OH)2D3 was unchanged in the present study, indi-
cating that an increase in CYP27B1 or a decrease in
CYP24 or both may be necessary. Our data suggest that
the decrease in CYP24 first occurs and the increase in
CYP27B1 comes into play later. The reciprocal regula-
tion of synthesizing and degradative enzymes forms a
general scheme of 1,25(OH)2D3 metabolism [30, 31].
The present study clearly demonstrated the increase in
CYP27B1 and the decrease in CYP24 expression in the
moderate chronic renal failure. In addition, the increase
in CYP27B1 mRNA may be supported by a previous
finding in which renal 25(OH)D3-1-hydroxylase after
uninephrectomy was unchanged in a unit of animal but
increased in a unit of mg DNA before hypertrophy [32].
Theoretically, when one-fourth of the kidney is resected,
a fourfold increase in CYP27B1 mRNA is required in
order to maintain the plasma 25(OH)D3 level. In this
regard, the down-regulation of CYP24 may play a more
important role in the very early stage of renal failure
than CYP27B1.
The recent observation from the megalin knockout
experiment has added a new scheme to the conventional
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framework of vitamin D metabolism. Nykjaer et al [6]
have shown that circulating 25(OH)D3 in complex with
vitamin D binding protein (DBP) is filtered through the
glomerulus and reabsorbed in the proximal tubules by
the endocytic receptor megalin. Thus, abnormal urinary
excretion of 25(OH)D3 and DBP seen in megalin knock-
out mice results in severe vitamin D deficiency and bone
disease [6]. In the present study, we found the expression
of megalin mRNA greatly decreased in the remnant kid-
ney of the nephrectomized rats. In this setting, the num-
ber of 25(OH)D3 molecules taken up via the megalin
pathway might be tremendously reduced in the proximal
tubular cells because the GFR also declines. Given the
unaltered plasma 1,25(OH)2D3 level, two compensatory
mechanisms are conceivable. Most probably, the coordi-
nated changes in both the marked increase in CYP27B1
and decrease in CYP24 could overcome the dramatic de-
cline of megalin expression. Alternatively, some synthesis
of 1,25(OH)2D3 is maintained by nonmegalin-mediated
mechanisms; several groups have reported the expres-
sion of CYP27B1 in more distal segments of the nephron
[33] and at extrarenal sites [34]. Although the decreased
expression of megalin has not been reported previously,
more studies need to be done to determine why megalin
mRNA decreases in the early stage of renal failure and
to clarify its pathophysiologic implication.
CONCLUSION
The present study demonstrates that in moderate renal
failure CYP27B1 mRNA remarkably increases with a
reciprocal alteration of CYP24 mRNA. A dramatic vari-
ation of the two key enzymes for vitamin D activation
and degradation accounts for an effective compensatory
mechanism in the face of reduced nephron mass and
down-regulation of megalin mRNA. However, the signal
for this reciprocal alteration of the two enzymes remains
unclear in the present study, although PTH and VDR
may partly contribute to this pathophysiology. Our pres-
ent findings elucidate the molecular mechanism of the
elaborate vitamin D metabolism in moderate renal fail-
ure, and thus provide new insights into the understanding
and potential treatment of secondary hyperparathyroid-
ism.
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